Literature DB >> 9712743

Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice.

J U Igietseme1, I M Uriri, S N Kumar, G A Ananaba, O O Ojior, I A Momodu, D H Candal, C M Black.   

Abstract

The induction of local T helper type 1 (Th1)-mediated cellular immunity is crucial for resistance of mice to genital infection by the obligate intracellular bacterium Chlamydia trachomatis. We tested the hypothesis that the route of immunization that elicits relatively high numbers of chlamydia-specific, gamma interferon (IFN-gamma)-secreting T lymphocytes (ISTLs) in the genital tract would induce optimal protective immunity against reinfection. Female BALB/c mice were infected intravaginally (i.v.), intranasally (i.n.), orally (p.o.), or subcutaneously (s.c.) with C. trachomatis. At days 7, 14, 21, and 28 postinfection, T cells isolated from the genital tract tissues were restimulated with chlamydial antigen in vitro, and the amounts of IFN-gamma induced were measured by a sandwiched enzyme-linked immunosorbent assay method. At day 7 postinfection, i.n.- and i.v.-immunized mice had high levels of chlamydia-specific ISTLs in their genital tracts (203.58 +/- 68.1 and 225.5 +/- 12.1 pg/ml, respectively). However, there were no detectable ISTLs in the genital tracts of p.o.- or s.c.-infected mice. When preinfected mice were challenged i.v. 70 days later, animals preexposed by the i.n. route were highly resistant to reinfection, with greatly reduced chlamydial burden, and suffered an attenuated infection that resolved by day 6 postchallenge. Animals preexposed by the i.v. route were modestly protected, whereas p.o. and s.c. groups were indistinguishable in this regard from control mice. The resistance of i.n.-immunized mice (and to some extent the i.v.-exposed mice) to reinfection was associated with early appearance (within 24 h) of high levels of genital ISTLs compared with mice preinfected by other routes. Furthermore, although i.n. and i.v.-immunized mice had comparable levels of chlamydia-specific immunoglobulin A (IgA) antibodies in their vaginal washes, the levels of IgG2a were four- sixfold higher in i.n.-immunized mice than in any of the other groups. The results suggested that immunization routes that foster rapid induction of vigorous genital mucosal cell-mediated immune (CMI) effectors (e.g., IFN-gamma), the CMI-associated humoral effector, IgG2a, and to some extent secretory IgA produce protective immunity against chlamydial genital infection. Therefore, i.n. immunization is a potential delivery route of choice in the development of a vaccine against Chlamydia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712743      PMCID: PMC108481          DOI: 10.1128/IAI.66.9.4030-4035.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

Review 1.  The mucosal immune system: from fundamental concepts to vaccine development.

Authors:  J R McGhee; J Mestecky; M T Dertzbaugh; J H Eldridge; M Hirasawa; H Kiyono
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

Review 2.  Mucosal immunity: implications for vaccine development.

Authors:  J Holmgren; C Czerkinsky; N Lycke; A M Svennerholm
Journal:  Immunobiology       Date:  1992-02       Impact factor: 3.144

Review 3.  Antiparasitic effects of nitric oxide in an in vitro murine model of Chlamydia trachomatis infection and an in vivo murine model of Leishmania major infection.

Authors:  M L Woods; J Mayer; T G Evans; J B Hibbs
Journal:  Immunol Ser       Date:  1994

Review 4.  New strategies for using mucosal vaccination to achieve more effective immunization.

Authors:  R I Walker
Journal:  Vaccine       Date:  1994-04       Impact factor: 3.641

5.  Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge.

Authors:  S Pal; I Theodor; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines.

Authors:  K H Ramsey; R G Rank
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

7.  Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis.

Authors:  S Pal; T J Fielder; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Protection against vaginal SIV transmission with microencapsulated vaccine.

Authors:  P A Marx; R W Compans; A Gettie; J K Staas; R M Gilley; M J Mulligan; G V Yamshchikov; D Chen; J H Eldridge
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

9.  Effect of gamma interferon on resolution of murine chlamydial genital infection.

Authors:  R G Rank; K H Ramsey; E A Pack; D M Williams
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

10.  Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 lymphocyte clone.

Authors:  J U Igietseme; K H Ramsey; D M Magee; D M Williams; T J Kincy; R G Rank
Journal:  Reg Immunol       Date:  1993 Nov-Dec
View more
  35 in total

1.  Urethral cytokine and immune responses in Chlamydia trachomatis-infected males.

Authors:  M S Pate; S R Hedges; D A Sibley; M W Russell; E W Hook; J Mestecky
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

2.  A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males.

Authors:  Sukumar Pal; Annahita K Sarcon; Luis M de la Maza
Journal:  Vaccine       Date:  2010-10-13       Impact factor: 3.641

3.  The intercellular adhesion molecule type-1 is required for rapid activation of T helper type 1 lymphocytes that control early acute phase of genital chlamydial infection in mice.

Authors:  J U Igietseme; G A Ananaba; J Bolier; S Bowers; T Moore; T Belay; D Lyn; C M Black
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

4.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

5.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

6.  Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo.

Authors:  R A Hawkins; R G Rank; K A Kelly
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

7.  Protective immunity against Chlamydia trachomatis can engage both CD4+ and CD8+ T cells and bridge the respiratory and genital mucosae.

Authors:  Catarina V Nogueira; Xuqing Zhang; Nicholas Giovannone; Erica L Sennott; Michael N Starnbach
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

8.  Cytokine expression pattern in the genital tract of Chlamydia trachomatis positive infertile women - implication for T-cell responses.

Authors:  B S Reddy; S Rastogi; B Das; S Salhan; S Verma; A Mittal
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

9.  Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.

Authors:  Qing He; Alaina Mitchell; Tulin Morcol; Steve J D Bell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

10.  Modulation of cytokines and transcription factors (T-Bet and GATA3) in CD4 enriched cervical cells of Chlamydia trachomatis infected fertile and infertile women upon stimulation with chlamydial inclusion membrane proteins B and C.

Authors:  Rishein Gupta; Harsh Vardhan; Pragya Srivastava; Sudha Salhan; Aruna Mittal
Journal:  Reprod Biol Endocrinol       Date:  2009-08-22       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.